Real-time nucleic acid amplification-based qualitative assay for specific genotyping of E6/E7 mRNA from HPV 16, 18, and 45.
A useful tool to identify young women at risk for developing Cervical Cancer.
1 Munoz N, Int. J. Cancer: 111,278-285(2004).
PreTect SEE® is based on NASBA technology, an enzymatic amplification process that can amplify and detect RNA even in the presence of DNA. Unlike PCR, an amplification run is performed under isothermal conditions at 41°C, achieving a fast result.
PreTect SEE identifies cancer development caused by the three most important HPV types documented to be related to cervical cancer. These three HPV types are related to >90 % of all cervical cancer cases in women <35 years of age and > 80 % of all cervical cancer cases in women aged 35 to 49 years.1 Over 20 other HPV types have also been associated with cervical cancer. However, the number of women developing cervical cancer related to all these other HPV types is very limited, especially in women below 50 years of age.
1 Munoz (2004)
Other DNA/RNA tests have significantly lower specificity than cytology. PreTect SEE has significantly higher accuracy and specificity than cytology. This implies that the number of women in need of follow-up, and thereby the follow-up cost, will be reduced by 60-70 % compared to the use of other DNA/RNA tests.
A DNA test only detects the presence of HPV while PreTect SEE detects the oncogene activity (full length E6/E7 transcript) from HPV 16, 18, and 45.
PreTect SEE is clinically validated according to the EU IVD regulations.
We develop medical devices and safe, state-of-the-art molecular technologies that empower you to take control of your health through prevention.
Learn about the new technologies we’re developing for personalized medicine.
Have Questions? Our team is happy to answer any questions you may have.
